RG-7388 (149), also known as idasanutlin, is the first potent oral MDM2 protein inhibitor developed by Roche.399 With its exceptional activity and selectivity, RG-7388 can effectively activate the p53 pathway, induce wild type p53 expression, trigger cell cycle block or apoptosis, and inhibit tumor proliferation in neuroblastoma transplant tumor. Here, MDM2 is linked to neoplasm.